Relevance of irinotecan hydrochloride-induced diarrhea to the level of prostaglandin E2 and water absorption of large intestine in rats

Japanese Journal of Pharmacology

Volumn 75, Issue 4, 1997, Pages 399-405

  Kase, Yoshio ^a   Hayakawa, Terumasa ^a   Togashi, Yuji ^a   Kamataki, Tetsuya ^b  

^a TSUMURA AND CO   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Colon; CPT 11 (irinotecan hydrochloride); Diarrhea; Prostaglandin E2; Side effect

Indexed keywords

ATROPINE; INDOMETACIN; IRINOTECAN; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CHOLINERGIC SYSTEM; COLON ABSORPTION; CONTROLLED STUDY; DEGENERATION; DESCENDING COLON; DIARRHEA; DIGESTIVE SYSTEM INJURY; DOSE RESPONSE; GOBLET CELL; HISTOPATHOLOGY; ILEUM; INTESTINE CRYPT; INTESTINE VILLUS; INTRAVENOUS DRUG ADMINISTRATION; LARGE INTESTINE; MALE; NECROSIS; NONHUMAN; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; WATER ABSORPTION;

EID: 0031446757     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.75.399     Document Type: Article

References (25)

1. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y and Okada K: Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84, 5565-5569 (1987)
2. Kaneda N, Nagata H, Furuta T and Yokokura T: Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50, 1715-1720 (1990)
3. Kawato Y, Aomura M, Hirota Y, Kuga H and Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51, 4187-4191 (1991)
4. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T and Ogawa N: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11, 909-913 (1993)
5. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H and Taguchi T: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83, 1164-1168 (1991)
6. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S and Taguchi T: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10, 16-20 (1992)
7. Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Nakagawa K, Hirashima T, Tamanoi M, Nitta T, Yana T, Negoro S, Takifuji N and Takada M: Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 12, 90-96 (1994)
8. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimura M, Sakai Y, Oguro M, Ito Y, Morishima Y, Yokomaku S and Ota K: An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8, 1907-1912 (1990)
9. Hawkey CJ and Rampton DS: Prostaglandins and the gastrointestinal mucosa: Are they important in its function, disease, or treatment? Gastroenterology 89, 1162-1188 (1985)
10. Madsen JR, Bukhave K and Beubler E: Influence on intesinal secretion of eicosanoids. J Intern Med Suppl 732, 137-144 (1990)
11. 2-induced diarrhea in mice: Importance of colonie secretion. J Pharmacol Exp Ther 256, 547-552 (1991)
12. Takasuna K, Kasai Y, Kitano Y, Mori K, Kakihata K, Hirohashi M and Nomura M: Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Folia Pharmacol Jpn 105, 447-460 (1995) (Abstr in English)
13. Kobayashi K, Arakawa T, Nakamura H, Chono S, Yamada H and Yamamoto S: Determination of prostaglandins and the effect of indomethacin on rat gastric mucosa. Tohoku J Exp Med 135, 371-378 (1981)
14. Fedorak RN, Empey LR, Macarthur C and Jewell LD: Misoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats. Gastroenterology 98, 615-625 (1990)
15. Thompson WG: The irritable bowel. Gut 25, 305-320 (1984)
16. Rampton DS and Hawkey CJ: Prostaglandins and ulcerative colitis. Gut 25, 1399-1413 (1984)
17. Narducci F, Snape WJ, Battle WM, London RL and Cohen S: Increased colonie motility during exposure to a stressful situation. Dig Dis Sci 30, 40-44 (1985)
18. Beubler E and Horina G: 5-HT2 and 5-HT3 receptor subtypes mediate cholera toxin-induced intestinal fluid secretion in the rat. Gastroenterology 99, 83-89 (1990)
19. Donowitz M: Arachidonic acid metabolites and their role in inflammatory bowel disease. Gastroenterology 88, 580-587 (1985)
20. Rampton DS: Functional aspects of eicosanoids in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1, 145-149 (1989)
21. 2 from activated eosinophils and macrophages in ulceative colitis. Am J Gastroenterol 90, 614-620 (1995)
22. Kawato Y, Sekiguchi M, Akahane K, Tsutomi Y, Hirota Y, Kuga H, Suzuki W, Hakusui H and Sato K: Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats. J Pharm Pharmacol 45, 444-448 (1993)
23. 2 and water absorption in large intestine of rats. Biol Pharm Bull 20, 954-957 (1997)
24. Atsumi R, Suzuki W and Hakusui H: Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21, 1159-1169 (1991)
25. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T and Kamataki T: Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56, 3752-3757 (1996)